Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Aspirin in the prevention of preeclampsia: the conundrum of how, who and when

Journal of Human Hypertension volume 33, pages 1–9 (2019)Cite this article

Subjects

Abstract

Aspirin is widely used in preventing early onset preeclampsia in women who are identified as being high risk. Although the benefit of aspirin is increasingly evident and acknowledged, there remains many unanswered questions with regards to its optimal application in pregnancy. The issues mainly centre around the relatively modest risk reduction that is observed with the use of aspirin prophylactically. We aim to explore the reasons behind the conservative rate of benefit and aim to explore factors that are likely to influence the outcomes with the use of aspirin.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130–7.

    Google Scholar 

  2. Jeyabalan A. Epidemiology of preeclampsia: impact of obesity. Nutr Rev. 2013;71(Suppl 1):S18–25.

    PubMed  Google Scholar 

  3. Thornton C, Dahlen H, Korda A, Hennessy A. The incidence of preeclampsia and eclampsia and associated maternal mortality in Australia from population-linked datasets: 2000-2008. Am J Obstet Gynecol. 2013;208:476 e1–5.

    Google Scholar 

  4. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649–58.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992–1005.

    CAS  PubMed  Google Scholar 

  6. Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res. 2005;57(5 Pt 2):1R–7R.

    PubMed  Google Scholar 

  7. Makris A, Yeung KR, Lim SM, Sunderland N, Heffernan S, Thompson JF, et al. Placental growth factor reduces blood pressure in a uteroplacental ischemia model of preeclampsia in nonhuman primates. Hypertension. 2016;67:1263–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Onda K, Tong S, Beard S, Binder N, Muto M, Senadheera SN, et al. Proton pump inhibitors decrease soluble fms-like tyrosine kinase-1 and soluble endoglin secretion, decrease hypertension, and rescue endothelial dysfunction. Hypertension. 2017;69:457–68.

    CAS  PubMed  Google Scholar 

  9. Thadhani R, Hagmann H, Schaarschmidt W, Roth B, Cingoez T, Karumanchi SA, et al. Removal of soluble Fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J Am Soc Nephrol. 2016;27:903–13.

    CAS  PubMed  Google Scholar 

  10. Wester-Rosenlof L, Casslen V, Axelsson J, Edstrom-Hagerwall A, Gram M, Holmqvist M, et al. A1M/alpha1-microglobulin protects from heme-induced placental and renal damage in a pregnant sheep model of preeclampsia. PLoS ONE. 2014;9:e86353.

    PubMed  PubMed Central  Google Scholar 

  11. Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377:613–22.

    CAS  PubMed  Google Scholar 

  12. Meher S, Duley L, Hunter K, Askie L. Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol. 2017;216:121–8 e2.

    CAS  PubMed  Google Scholar 

  13. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116(2 Pt 1):402–14.

    PubMed  Google Scholar 

  14. Lowe SA, Bowyer L, Lust K, McMahon LP, Morton M, North RA, et al. SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. Aust N Z J Obstet Gynaecol. 2015;55:e1–29.

    PubMed  Google Scholar 

  15. Redman CW. Hypertension in pregnancy: the NICE guidelines. Heart. 2011;97:1967–9.

    CAS  PubMed  Google Scholar 

  16. Park F, Russo K, Williams P, Pelosi M, Puddephatt R, Walter M, et al. Prediction and prevention of early-onset pre-eclampsia: impact of aspirin after first-trimester screening. Ultrasound Obstet Gynecol. 2015;46:419–23.

    CAS  PubMed  Google Scholar 

  17. Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216:110–20 e6.

    CAS  PubMed  Google Scholar 

  18. Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2009;30:426–35.

    PubMed  Google Scholar 

  19. Kuliczkowski W, Halawa B, Korolko B, Mazurek W. Aspirin resistance in ischaemic heart disease. Kardiol Pol. 2005;62:14–25.

    PubMed  Google Scholar 

  20. Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int. 2013;30:260–79.

    CAS  PubMed  Google Scholar 

  21. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest. 1975;56:624–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Goodlin RC, Haesslein HO, Fleming J. Aspirin for the treatment of recurrent toxaemia. Lancet (Lond, Engl). 1978;2:51.

    CAS  Google Scholar 

  23. Walsh SW. Thromboxane production in placentas of women with preeclampsia. Am J Obstet Gynecol. 1989;160:1535–6.

    CAS  PubMed  Google Scholar 

  24. Walsh SW. Physiology of low-dose aspirin therapy for the prevention of preeclampsia. Semin Perinatol. 1990;14:152–70.

    CAS  PubMed  Google Scholar 

  25. Beaufils M, Uzan S, Donsimoni R, Colau JC. Prevention of pre-eclampsia by early antiplatelet therapy. Lancet (Lond, Engl). 1985;1:840–2.

    CAS  Google Scholar 

  26. Uzan S, Beaufils M, Breart G, Bazin B, Capitant C, Paris J. Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. Lancet (Lond, Engl). 1991;337:1427–31.

    CAS  Google Scholar 

  27. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet (Lond, Engl). 1994;343:619–29.

  28. Rotchell YE, Cruickshank JK, Gay MP, Griffiths J, Stewart A, Farrell B, et al. Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. Br J Obstet Gynaecol. 1998;105:286–92.

    CAS  PubMed  Google Scholar 

  29. Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1998;338:701–5.

    CAS  PubMed  Google Scholar 

  30. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA, Group PC. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet (Lond, Engl). 2007;369:1791–8.

    CAS  Google Scholar 

  31. Sibai BM, Caritis SN, Thom E, Shaw K, McNellis D. Low-dose aspirin in nulliparous women: safety of continuous epidural block and correlation between bleeding time and maternal-neonatal bleeding complications. National Institute of Child Health and Human Developmental Maternal-Fetal Medicine Network. Am J Obstet Gynecol. 1995;172:1553–7.

    CAS  PubMed  Google Scholar 

  32. Schiff E, Peleg E, Goldenberg M, Rosenthal T, Ruppin E, Tamarkin M, et al. The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. N Engl J Med. 1989;321:351–6.

    CAS  PubMed  Google Scholar 

  33. Viinikka L, Hartikainen-Sorri AL, Lumme R, Hiilesmaa V, Ylikorkala O. Low dose aspirin in hypertensive pregnant women: effect on pregnancy outcome and prostacyclin-thromboxane balance in mother and newborn. Br J Obstet Gynaecol. 1993;100:809–15.

    CAS  PubMed  Google Scholar 

  34. Roberts MS, Joyce RM, McLeod LJ, Vial JH, Seville PR. Slow-release aspirin and prostaglandin inhibition. Lancet (Lond, Engl). 1986;1:1153–4.

    CAS  Google Scholar 

  35. Sibai BM, Mirro R, Chesney CM, Leffler C. Low-dose aspirin in pregnancy. Obstet Gynecol. 1989;74:551–7.

    CAS  PubMed  Google Scholar 

  36. Haapsamo M, Martikainen H, Rasanen J. Low-dose aspirin reduces uteroplacental vascular impedance in early and mid gestation in IVF and ICSI patients: a randomized, placebo-controlled double-blind study. Ultrasound Obstet Gynecol. 2008;32:687–93.

    CAS  PubMed  Google Scholar 

  37. Coomarasamy A, Papaioannou S, Gee H, Khan KS. Aspirin for the prevention of preeclampsia in women with abnormal uterine artery Doppler: a meta-analysis. Obstet Gynecol. 2001;98(5 Pt 1):861–6.

    CAS  PubMed  Google Scholar 

  38. Vainio M, Riutta A, Koivisto AM, Maenpaa J. Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders. Acta Obstet Gynecol Scand. 2004;83:1119–23.

    PubMed  Google Scholar 

  39. Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA. 1995;92:9475–9.

    CAS  PubMed  Google Scholar 

  40. Goh J, Baird AW, O’Keane C, Watson RW, Cottell D, Bernasconi G, et al. Lipoxin A(4) and aspirin-triggered 15-epi-lipoxin A(4) antagonize TNF-alpha-stimulated neutrophil-enterocyte interactions in vitro and attenuate TNF-alpha-induced chemokine release and colonocyte apoptosis in human intestinal mucosa ex vivo. J Immunol. 2001;167:2772–80.

    CAS  PubMed  Google Scholar 

  41. Ariel A, Chiang N, Arita M, Petasis NA, Serhan CN. Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. J Immunol. 2003;170:6266–72.

    CAS  PubMed  Google Scholar 

  42. Nascimento-Silva V, Arruda MA, Barja-Fidalgo C, Villela CG, Fierro IM. Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. Am J Physiol Cell Physiol. 2005;289:C557–63.

    CAS  PubMed  Google Scholar 

  43. Mitchell S, Thomas G, Harvey K, Cottell D, Reville K, Berlasconi G, et al. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol. 2002;13:2497–507.

    CAS  PubMed  Google Scholar 

  44. Chiang N, Takano T, Arita M, Watanabe S, Serhan CN. A novel rat lipoxin A4 receptor that is conserved in structure and function. Br J Pharmacol. 2003;139:89–98.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Gewirtz AT, Collier-Hyams LS, Young AN, Kucharzik T, Guilford WJ, Parkinson JF, et al. Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol. 2002;168:5260–7.

    CAS  PubMed  Google Scholar 

  46. Fierro IM, Kutok JL, Serhan CN. Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). J Pharmacol Exp Ther. 2002;300:385–92.

    CAS  PubMed  Google Scholar 

  47. Fiorucci S, Distrutti E, Mencarelli A, Morelli A, Laufor SA, Cirino G, et al. Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin. Br J Pharmacol. 2003;139:1351–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Chiang N, Hurwitz S, Ridker PM, Serhan CN. Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: a randomized human trial. Arterioscler Thromb Vasc Biol. 2006;26:e14–7.

    CAS  PubMed  Google Scholar 

  49. Alvarez AM, Mulla MJ, Chamley LW, Cadavid AP, Abrahams VM. Aspirin-triggered lipoxin prevents antiphospholipid antibody effects on human trophoblast migration and endothelial cell interactions. Arthritis Rheumatol. 2015;67:488–97.

    CAS  PubMed  Google Scholar 

  50. Gil-Villa AM, Norling LV, Serhan CN, Cordero D, Rojas M, Cadavid A. Aspirin triggered-lipoxin A4 reduces the adhesion of human polymorphonuclear neutrophils to endothelial cells initiated by preeclamptic plasma. Prostaglandins Leukot Essent Fat Acids. 2012;87:127–34.

    CAS  Google Scholar 

  51. Zhangye XuMD, Feng Zhao MM, Feng Lin MM, Huiqiu Xiang MM, Ni Wang MM, Duyun Ye,MM, Yinping Huang MM. Preeclampsia is associated with a deficiency of lipoxin A4, an endogenous anti-inflammatory mediator. Fertil Steril. 2014;102:282–90.e4.

    Google Scholar 

  52. Lipa M, Bomba-Opon D, Lipa J, Bartnik P, Bartoszewicz Z, Wielgos M. Lipoxin A4 (LXA4) as a potential first trimester biochemical marker of intrauterine growth disorders. J Matern Fetal Neonatal Med. 2017;30:2495–7.

    CAS  PubMed  Google Scholar 

  53. Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens. 2010;24:104–10.

    CAS  PubMed  Google Scholar 

  54. North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, et al. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ. 2011;342:d1875.

    PubMed  PubMed Central  Google Scholar 

  55. Visintin C, Mugglestone MA, Almerie MQ, Nherera LM, James D, Walkinshaw S, et al. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ. 2010;341:c2207.

    PubMed  Google Scholar 

  56. Onwudiwe N, Yu CK, Poon LC, Spiliopoulos I, Nicolaides KH. Prediction of pre-eclampsia by a combination of maternal history, uterine artery Doppler and mean arterial pressure. Ultrasound Obstet Gynecol. 2008;32:877–83.

    CAS  PubMed  Google Scholar 

  57. Poon LC, Kametas NA, Valencia C, Chelemen T, Nicolaides KH. Hypertensive disorders in pregnancy: screening by systolic diastolic and mean arterial pressure at 11-13 weeks. Hypertens Pregnancy. 2011;30:93–107.

    PubMed  Google Scholar 

  58. Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33:8–15.

    PubMed  Google Scholar 

  59. Tranquilli AL. Introduction to ISSHP new classification of preeclampsia. Pregnancy Hypertens. 2013;3:58–9.

    PubMed  Google Scholar 

  60. Zvanca ME, Bot M, Radu D, Radu N, Petca A. Impact of early supplementation with low-dose aspirin on functional first trimester parameters in low-risk pregnancies. J Matern Fetal Neonatal Med. 2017:1–6. https://doi.org/10.1080/14767058.2017.1387532

    Google Scholar 

  61. Hermida RC, Ayala DE, Calvo C, Lopez JE. Aspirin administered at bedtime, but not on awakening, has an effect on ambulatory blood pressure in hypertensive patients. J Am Coll Cardiol. 2005;46:975–83.

    CAS  PubMed  Google Scholar 

  62. Hermida RC, Ayala DE, Calvo C, Lopez JE, Fernandez JR, Mojon A, et al. Administration time-dependent effects of aspirin on blood pressure in untreated hypertensive patients. Hypertension. 2003;41:1259–67.

    CAS  PubMed  Google Scholar 

  63. Hermida RC, Ayala DE, Calvo C, Lopez JE, Mojon A, Rodriguez M, et al. Differing administration time-dependent effects of aspirin on blood pressure in dipper and non-dipper hypertensives. Hypertension. 2005;46:1060–8.

    CAS  PubMed  Google Scholar 

  64. Kanzik I, Cakici I, Ersoy S, Ark M, Abacioglu N, Zengil H. Effects of cyclooxygenase and lipoxygenase inhibitors on digoxin-induced arrhythmias and haemodynamics in guinea-pigs. Pharmacol Res. 1992;26:305–16.

    CAS  PubMed  Google Scholar 

  65. Snoep JD, Hovens MM, Pasha SM, Frolich M, Pijl H, Tamsma JT, et al. Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines. Hypertension. 2009;54:1136–42.

    CAS  PubMed  Google Scholar 

  66. Cornelissen G, Halberg F, Prikryl P, Dankova E, Siegelova J, Dusek J. Prophylactic aspirin treatment: the merits of timing. International Womb-to-Tomb Chronome Study Group. JAMA. 1991;266:3128–9.

    CAS  PubMed  Google Scholar 

  67. Hermida RC, Ayala DE, Fernandez JR, Mojon A, Alonso I, Silva I, et al. Administration time-dependent effects of aspirin in women at differing risk for preeclampsia. Hypertension. 1999;34(4 Pt 2):1016–23.

    CAS  PubMed  Google Scholar 

  68. Caron N, Rivard GE, Michon N, Morin F, Pilon D, Moutquin JM, et al. Low-dose ASA response using the PFA-100 in women with high-risk pregnancy. J Obstet Gynaecol Can. 2009;31:1022–7.

    PubMed  Google Scholar 

  69. Lee PY, Chen WH, Ng W, Cheng X, Kwok JY, Tse HF, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med. 2005;118:723–7.

    CAS  PubMed  Google Scholar 

  70. Benigni A, Gregorini G, Frusca T, Chiabrando C, Ballerini S, Valcamonico A, et al. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med. 1989;321:357–62.

    CAS  PubMed  Google Scholar 

  71. Cuisset T, Frere C, Quilici J, Gaborit B, Bali L, Poyet R, et al. Aspirin noncompliance is the major cause of “aspirin resistance” in patients undergoing coronary stenting. Am Heart J. 2009;157:889–93.

    CAS  PubMed  Google Scholar 

  72. Navaratnam K, Alfirevic A, Jorgensen A, Alfirevic Z. Aspirin non-responsiveness in pregnant women at high-risk of pre-eclampsia. Eur J Obstet Gynecol Reprod Biol. 2018;221:144–50.

    CAS  PubMed  Google Scholar 

  73. Lupattelli A, Spigset O, Nordeng H. Adherence to medication for chronic disorders during pregnancy: results from a multinational study. Int J Clin Pharm. 2014;36:145–53.

    Google Scholar 

  74. Julsgaard M, Norgaard M, Hvas CL, Buck D, Christensen LA. Self-reported adherence to medical treatment prior to and during pregnancy among women with ulcerative colitis. Inflamm Bowel Dis. 2011;17:1573–80.

    PubMed  Google Scholar 

  75. Sawicki E, Stewart K, Wong S, Leung L, Paul E, George J. Medication use for chronic health conditions by pregnant women attending an Australian maternity hospital. Aust N Z J Obstet Gynaecol. 2011;51:333–8.

    Google Scholar 

  76. Abheiden CN, van Reuler AV, Fuijkschot WW, de Vries JI, Thijs A, de Boer MA. Aspirin adherence during high-risk pregnancies, a questionnaire study. Pregnancy Hypertens. 2016;6:350–5.

    PubMed  Google Scholar 

  77. Wright D, Poon LC, Rolnik DL, Syngelaki A, Delgado JL, Vojtassakova D, et al. Aspirin for evidence-based preeclampsia prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. Am J Obstet Gynecol. 2017;217:685e1–e5.

    Google Scholar 

  78. Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke. 2006;37:2153–8.

    CAS  PubMed  Google Scholar 

  79. Van Hecken A, Juliano ML, Depre M, De Lepeleire I, Arnout J, Dynder A, et al. Effects of enteric-coated, low-dose aspirin on parameters of platelet function. Aliment Pharmacol Ther. 2002;16:1683–8.

    PubMed  Google Scholar 

  80. Karha J, Rajagopal V, Kottke-Marchant K, Bhatt DL. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. Am Heart J. 2006;151:976 e7–11.

    Google Scholar 

Download references

Acknowledgements

We thank Mr Rajeev Wijesekera for his assistance with the design of the illustrations used in this manuscript.

Author contributions

RS, AH, and AM contributed equally and collaboratively in the literature review, proof reading, and preparation of this manuscript.

Funding

None to declare.

Author information

Authors and Affiliations

  1. Department of Renal Medicine, South Western Sydney Local Health District, Sydney, NSW, Australia

    Renuka Shanmugalingam, Annemarie Hennessy & Angela Makris

  2. School of Medicine, Western Sydney University, Sydney, NSW, Australia

    Renuka Shanmugalingam, Annemarie Hennessy & Angela Makris

Authors
  1. Renuka Shanmugalingam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annemarie Hennessy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angela Makris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Renuka Shanmugalingam.

Ethics declarations

Details of ethics approval

Not applicable.

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shanmugalingam, R., Hennessy, A. & Makris, A. Aspirin in the prevention of preeclampsia: the conundrum of how, who and when. J Hum Hypertens 33, 1–9 (2019). https://doi.org/10.1038/s41371-018-0113-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41371-018-0113-7

This article is cited by

Search

Advanced search

Quick links